PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors.
Our key offerings include:
Transactions / deal negotiations;
Product / technology valuations;
Deal term advice;
Due diligence & expert reports;
Strategy formulation;
Alliance management; and
Expert opinion for litigation/arbitration cases.
PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Merck Serono
Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. In the United States and Canada, EMD Serono operates as a separately incorporated affiliate of Merck Serono.
Merck Serono has leading brands serving patients with cancer Erbitux, cetuximab), multiple sclerosis (Rebif, interferon-beta-1a), infertility (Gonal-f, follitropinalfa), endocrine and metabolic disorders (Saizen and Serostim, somatropin), (Kuvan, sapropterin-dihydrochloride), (Egrifta, tesamorelin), as well as cardiometabolic diseases (Glucophage, metformin), (Concor, bisoprolol), (Euthyrox, levothyroxine). Not all products are available in all markets.
With an annual R&D expenditure of over 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases , oncology, fertility and endocrinology , as well as new areas potentially arising out of research and development in rheumatology .